804, 322 - 11 AVENUE SW, CALGARY, A0
Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Oncolytics Biotech Engages Baker Tilly as New Independent Auditor
Q2
Q1
FY 2025
Annual and Transition Report of Foreign Private Issuers
Administrative Withdrawal
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to a Registration Statement for Securities of Certain Canadian Issuers